SYSTEMIC LUPUS ERYTHEMATOSUS

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to find the right dose and check if it's safe when used with standard treatments. Lupus is a long-term disease where the immune system attacks the body, and …

This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. YTB323 uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The trial will enroll 21 adults and focus on saf…

This study looks at the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). About 760 adults who completed a previous related study will receive the drug and be monitored for side effects over time. The goal is to see if the…

This study tests whether a daily pill called deucravacitinib can safely control lupus symptoms better than a placebo. About 516 adults with active moderate-to-severe lupus will take either the drug or a dummy pill for up to a year. The main goal is to see if more people on the dr…

This study compares two ways of giving the drug ianalumab to adults with autoimmune diseases like rheumatoid arthritis, Sjögren's disease, or lupus. The goal is to see if a single 2mL injection works as well as two separate 1mL injections. About 155 participants will receive both…

This early-phase study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty cells in active autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome. The goal is to see if it is safe and tolerable for up to …

This study tests whether afimetoran can safely control lupus disease activity better than a placebo. About 268 adults with active lupus will receive either the drug or a placebo for 48 weeks, with an extension period where placebo users can switch to afimetoran. The main goal is …

This study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.

This study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…

This study tests a gentle, non-invasive electromagnetic treatment to see if it can help calm overactive immune systems in people with lupus, rheumatoid arthritis, or multiple sclerosis. 120 adults will receive either real or placebo sessions three times a week for 12 weeks. The g…

This early-stage study tests whether specially engineered immune cells (CAR-T cells) can safely treat people with severe lupus that hasn't responded to standard treatments. About 22 participants will receive the cells and be monitored for side effects and signs of disease improve…

This study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and find the right dose. The study has two parts: one where participants get a single dose, and another where the dose is split over time. This …

This study aimed to test whether the drug telitacicept could help people with moderate-to-severe lupus better than a placebo. It was designed for people aged 12 to 70 with active lupus symptoms. However, the trial was withdrawn before enrolling any participants, so no results are…

This study tests whether lisinopril, a blood pressure drug that works in the brain, can improve memory and concentration in people with lupus. About 36 adults with lupus and cognitive issues will take either lisinopril or another ACE inhibitor for 12 months. Researchers will meas…

This study tests whether adding sirolimus to standard lupus treatments helps control active disease better than placebo. About 146 adults with active lupus will receive either sirolimus or a dummy pill for 24 weeks. The main goal is to see if more people achieve a meaningful redu…

This study looks at the long-term safety of a drug called enpatoran (M5049) for people with lupus, including those with skin or whole-body forms. About 379 participants who finished a previous 24-week study will take enpatoran for up to 48 more weeks. The main goal is to check fo…

This study tests a new medicine called MIL62 in 120 adults with lupus, a chronic autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The study is not a cure but a…

This study tests a new drug called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if it can better control disease activity compared to a placebo, while still using standard lupus treatments. …

This study was designed to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to see i…

This early-phase study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to standard therapies. SC291 uses donor immune cells engineered to target and destroy faulty immune cells driving the disease. The main goal is to check safe…

This phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and calm the overactive immune system in people with severe lupus or scleroderma. The goal is to see if it is safe and can control the disease. The trial involves 18 adults whose…

This study tests a drug called obinutuzumab in 303 people with active lupus. Participants receive either the drug or a placebo, along with their usual treatments. The goal is to see if obinutuzumab can reduce lupus symptoms and disease activity better than placebo alone.

This study tests a new medicine called SAR441344 for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 109 adults aged 18 to 70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug reduces lupus sympt…

This early-phase study tests a new treatment called NKX019 for people with systemic lupus erythematosus (SLE), an autoimmune disease. NKX019 uses specially engineered immune cells to target and destroy faulty B cells that drive the disease. The main goal is to check safety and to…

This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions …

This study looks back at medical records of 180 adults with lupus to compare two drugs, telitacicept and belimumab. The goal is to see which one works better at controlling the disease and has fewer side effects. Participants were already taking one of these drugs for at least 12…

This study tests whether N-acetylcysteine (NAC), a supplement, can help control lupus (SLE) symptoms and reduce the need for steroids. About 290 adults with lupus will take NAC or a placebo for 13 months. The goal is to see if NAC improves disease activity and is safe to use.

This early-phase study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered natural killer (NK) cells to target and d…

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year, with some continuing for up to two more years.…

This study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…

This study aimed to test a new type of cell therapy (called CAR T-cells) in people with severe lupus or inflammatory myopathy that did not get better with standard treatments. The therapy uses donor cells to target and destroy faulty immune cells. However, the study was withdrawn…

This early-stage study tests a new treatment for people with severe lupus or scleroderma that hasn't improved with standard therapies. The treatment uses a person's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and fi…

This study looks at whether the Shingrix vaccine is safe and effective for preventing shingles in people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus. About 2,000 patients will receive the vaccine or a placebo, and researchers will monitor for disease fl…

This study looks at 500 adults with lupus to see if certain immune system markers can better predict who is at high risk for heart disease. Researchers will track changes in artery health over time using ultrasound. The goal is to improve heart risk assessment for people with lup…

This study was designed to follow women with rare autoimmune diseases (like lupus, arthritis, and scleroderma) during pregnancy to learn about complications and improve care. It was withdrawn before any participants were enrolled, so no results are available. The goal was to help…

This study looks at how lupus (SLE) is diagnosed, how it changes over time, and what treatments are used in everyday medical practice in Kazakhstan. About 509 adults with lupus will be followed to see how active their disease is, what medications they take, and how their health e…

This study is the first time a new drug, GSK4347859, is being tested in humans. The goal is to check its safety and how it behaves in the body. It involves 65 healthy adults and is currently on hold. The drug is being developed for lupus, an autoimmune disease.

This study tests a program called HOP-STEP that helps doctors talk to women with lupus about pregnancy planning and birth control. The goal is to improve how doctors document contraception use and pregnancy intentions, especially in clinics serving high-minority and low-income co…